Our new website is coming soon, give it a try now and let us have your feedback. Take me to the Beta



Register
Login:
Share:
Email Facebook Twitter


TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake
Exclusive: Hardman & Co Investor Forum - Severn Trent, Calculus Capital, Volta Finance, Residential


Summit Ther Regulatory News (SUMM)



Regulatory News for Summit Ther (SUMM)


Share Price: 23.75Bid: 22.50Ask: 25.00Change: 0.00 (0.00%)No Movement on Summit Ther
Spread: 2.50Spread as %: 11.11%Open: 23.75High: 23.75Low: 23.75Yesterday’s Close: 23.75





DateSourceHeadlineCategory
20-Jun-19 12:00Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019Company Announcement - General
19-Jun-19 12:00Result of AGMResults and Trading Reports
18-Jun-19 12:00Increased BARDA Award and Option ExerciseCompany Announcement - General
12-Jun-19 12:00Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019Results and Trading Reports
05-Jun-19 14:00Notice of First Quarter ResultsAdvance Notice of Results
14-May-19 17:30UK Annual Report and Notice of AGMResults and Trading Reports
29-Apr-19 12:30Block Listing Interim ReviewCompany Announcement - General
24-Apr-19 16:20Exercise of Restricted Stock UnitsCompany Announcement - General
15-Apr-19 07:00Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019Company Announcement - General
03-Apr-19 12:00Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting EnterobacteriaceaeCompany Announcement - General
02-Apr-19 12:00Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences ConferenceCompany Announcement - General
29-Mar-19 17:45Award of Share OptionsCompany Announcement - General
29-Mar-19 11:15Filing of Annual Report on Form 20-FCompany Announcement - General
27-Mar-19 11:00Final ResultsResults and Trading Reports
25-Mar-19 11:00Notice of ResultsAdvance Notice of Results
18-Mar-19 11:00Summit Therapeutics to Present at Upcoming ConferencesCompany Announcement - General
14-Mar-19 11:00Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 ConferenceCompany Announcement - General
25-Feb-19 12:00Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical DataCompany Announcement - General
13-Feb-19 12:00Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile InfectionCompany Announcement - General
08-Feb-19 12:00Summit Therapeutics to Present at the BIO CEO & Investor ConferenceCompany Announcement - General
15-Jan-19 17:45Holding(s) in CompanyHolding(s) in Company
14-Jan-19 12:00Award of Restricted Stock UnitsCompany Announcement - General
10-Jan-19 16:15Holding(s) in CompanyHolding(s) in Company
10-Jan-19 11:30Holding(s) in CompanyHolding(s) in Company
09-Jan-19 16:45Holding(s) in CompanyHolding(s) in Company
08-Jan-19 07:00Update on AdmissionCompany Announcement - General
04-Jan-19 12:30Result of General MeetingResults and Trading Reports
02-Jan-19 09:40Holding(s) in CompanyHolding(s) in Company
18-Dec-18 12:15Holding(s) in CompanyHolding(s) in Company
17-Dec-18 07:05Proposed Subscription to Raise $25m and Notice of General MeetingCompany Announcement - General


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk




Home  |  Contact Us  |  About Us  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy  |  Mobile Site  |  About this website design


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.